This section is designed to provide quick and easy access to the latest information and top news on RADIESSE dermal filler, the next generation, FDA-approved dermal filler that provides both immediate and long-lasting correction for the signs of HIV-Associated Facial Lipoatrophy – a common side effect from highly active antiretroviral therapy (HAART).
With its recent FDA-approval, RADIESSE treatment is now garnering positive coverage from print and broadcast media across the United States. To learn more about the success of RADIESSE dermal filler, please view the news reports and articles below.
Long-Lasting Filler from BioForm Medical Approved for Treatment of Facial Wrinkles and Folds; and for the Correction of HIV-Associated Facial Wasting - December 27, 2006
General and Plastic Surgery Devices Advisory Panel Determines RADIESSE Safe and Effective in Correcting Facial Wrinkles and Folds and in the Restorative Treatment of HIV-Associated Facial Lipoatrophy - August 24, 2006
Leading Canadian Distributor Canderm Pharma will Launch RADIESSE dermal filler to Plastic Surgeons and Dermatologists Seeking a Long-Lasting, Non-Permanent Filler for Facial Aesthetics - November 10, 2005
BioForm Medical to File RADIESSE for Facial Soft Tissue Approval- September 28, 2005